CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 2, 2008--Alkermes, Inc. (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live by JPMorgan on Wednesday, January 9, 2008 at 12:30 p.m. EST (9:30 a.m. PST). David Broecker, CEO of Alkermes, will provide a strategic overview of the company and review the company's corporate goals for calendar 2008. The presentation will be webcast from the Westin St. Francis Hotel in San Francisco, California and may be accessed under the investor relation's tab at www.alkermes.com. The presentation will be archived for 30 days.
Alkermes, Inc. is a biotechnology company that uses proprietary technologies and know-how to create innovative medicines designed to yield better therapeutic outcomes for patients with serious disease. Alkermes manufactures RISPERDAL(R) CONSTA(R), marketed by Janssen-Cilag (Janssen, L.P.), a wholly owned division of Johnson & Johnson, and developed and manufactures VIVITROL(R), marketed in the U.S. primarily by Cephalon, Inc. The company's pipeline includes extended-release injectable, pulmonary and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Alkermes is headquartered in Cambridge, Massachusetts, with research and manufacturing facilities in Massachusetts and Ohio.
CONTACT: Alkermes, Inc.
Debra Koufos, 617-583-6220
Associate, Corporate Communications
SOURCE: Alkermes